Hikma Discusses Quality Vs Quantity Approach At Jefferies

The CEO Also Commented On The Potential Impact Of Trump’s Presidency

Hikma aims to launch fewer, but more material, products in the coming years as part of a shift in its research and development strategy that was discussed in a Q&A at this year’s Jefferies Healthcare Conference.

• Source: Shutterstock

Hikma Pharmaceuticals is in the midst of a shift in its research and development strategy that will prioritize fewer but higher-value products over a larger number of drugs that represent smaller-scale opportunities, per a Q&A at this year’s Jefferies Healthcare Conference in London in late November.

Attended by Hikma’s chief executive officer Riad Mishlawi and the company’s chief financial officer Khalid Nabilsi, the Q&A session provided an overview of the pharmaceutical firm’s latest efforts and strategic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

29 May 2025

• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

28 May 2025

• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

28 May 2025

• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.